XII Medical is a medical device developer company. It develops a minimally invasive outpatient technology for the treatment of obstructive sleep apnea.
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
PetDx is a molecular diagnostics company founded in 2019 that specializes in the early detection and treatment of cancer in pets. The company focuses on developing non-invasive tests utilizing customized assays and next-generation sequencing techniques. This innovative approach enables veterinarians to detect, characterize, and manage cancer cells more effectively, improving outcomes for pets with cancer. By offering advanced liquid biopsy technology, PetDx aims to transform veterinary oncology through enhanced diagnostic capabilities.
Cortica Inc. is a healthcare company focused on providing neurological therapies for children with autism and other neurodevelopmental challenges. Established in 2014 and based in San Diego, California, Cortica offers personalized treatment programs that are tailored to each child's neurobiology and developmental profile. The company employs a multidisciplinary approach, utilizing insights from emerging neuroscience to deliver comprehensive care through in-home, in-clinic, and telehealth services. Its offerings include evidence-based therapies such as applied behavior analysis (ABA), speech therapy, and occupational therapy, all aimed at fostering independent living, educational opportunities, and social relationships for children with developmental differences. Cortica operates multiple centers in California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Cortica Inc. is a healthcare company focused on providing neurological therapies for children with autism and other neurodevelopmental challenges. Established in 2014 and based in San Diego, California, Cortica offers personalized treatment programs that are tailored to each child's neurobiology and developmental profile. The company employs a multidisciplinary approach, utilizing insights from emerging neuroscience to deliver comprehensive care through in-home, in-clinic, and telehealth services. Its offerings include evidence-based therapies such as applied behavior analysis (ABA), speech therapy, and occupational therapy, all aimed at fostering independent living, educational opportunities, and social relationships for children with developmental differences. Cortica operates multiple centers in California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Irvine, California, specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions and other diseases with high unmet needs. The company's lead product candidate, TP-03, is currently undergoing Phase IIb/III trials for the treatment of blepharitis caused by Demodex mite infestations, as well as meibomian gland disease. In addition to TP-03, Tarsus is advancing other candidates such as TP-04 for the treatment of rosacea and TP-05 aimed at Lyme disease prophylaxis and malaria reduction. With a focus on addressing significant market opportunities, Tarsus Pharmaceuticals is committed to providing first-in-class therapies where treatment options are currently limited.
ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.
Verix Health is developing a suite of actively steerable surgical devices enabling minimally invasive diagnosis and treatment of lesions in difficult-to-access anatomies. The company was founded by Professor Mark Yim, PhD and PCI Ventures at the University of Pennsylvania and incubated at the Pennovation Center in Philadelphia.
Bardy Diagnostics, Inc. is a medical device company that specializes in the development and manufacturing of cardiac monitoring solutions, primarily focused on arrhythmia detection. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight, discreet cardiac patch that can be worn comfortably for up to seven days, even during physical activities like exercise or showering. The CAM is designed with a unique hourglass shape to enhance comfort, particularly for female patients. Complementing the monitor is the BDxCONNECT patient management system, which allows healthcare providers to create and manage patient reports efficiently. By utilizing innovative P-wave centric ECG detection technology, Bardy Diagnostics aims to improve clinical management and outcomes for patients and their physicians. Founded in 2013, the company is headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey.
Cortica Inc. is a healthcare company focused on providing neurological therapies for children with autism and other neurodevelopmental challenges. Established in 2014 and based in San Diego, California, Cortica offers personalized treatment programs that are tailored to each child's neurobiology and developmental profile. The company employs a multidisciplinary approach, utilizing insights from emerging neuroscience to deliver comprehensive care through in-home, in-clinic, and telehealth services. Its offerings include evidence-based therapies such as applied behavior analysis (ABA), speech therapy, and occupational therapy, all aimed at fostering independent living, educational opportunities, and social relationships for children with developmental differences. Cortica operates multiple centers in California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Spirox, Inc. is a medical device company headquartered in Menlo Park, California, focused on improving the quality of life for patients suffering from nasal obstruction due to nasal valve collapse. Formerly known as Nasoform LLC, the company develops innovative solutions to address this common but often undertreated condition. Their flagship product, the LATERA absorbable nasal implant, aims to provide effective treatment for nasal valve collapse, enhancing nasal airflow and overall patient comfort. Founded in 2011, Spirox operates as a subsidiary of Entellus Medical, Inc. and is actively involved in completing product development, seeking U.S. marketing authorization, and initiating commercialization efforts.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Spirox, Inc. is a medical device company headquartered in Menlo Park, California, focused on improving the quality of life for patients suffering from nasal obstruction due to nasal valve collapse. Formerly known as Nasoform LLC, the company develops innovative solutions to address this common but often undertreated condition. Their flagship product, the LATERA absorbable nasal implant, aims to provide effective treatment for nasal valve collapse, enhancing nasal airflow and overall patient comfort. Founded in 2011, Spirox operates as a subsidiary of Entellus Medical, Inc. and is actively involved in completing product development, seeking U.S. marketing authorization, and initiating commercialization efforts.
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatment options for heart failure and associated cardiovascular conditions. The company's primary product is the Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach. This innovative device reshapes the mitral valve to reduce regurgitation, enabling less invasive procedures for patients. Founded in 2000 and headquartered in Kirkland, Washington, Cardiac Dimensions also has operations in Sydney, Australia, and Offenbach, Germany.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
Lyric Pharmaceuticals Inc. is a clinical-stage pharmaceutical company founded in 2013 and based in South San Francisco, California. The company focuses on developing novel gastrointestinal therapeutics aimed at addressing unmet medical needs in critically ill and hospitalized patients. One of its primary products, ulimorelin, is a macrocyclic agonist of the hormone ghrelin, being developed as LP101 for the treatment of enteral feeding intolerance and other gastrointestinal disorders in the intensive care unit. Lyric's portfolio includes pro-kinetic and pro-metabolic drugs designed to improve patient care in hospital settings.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.
Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.
Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.
Channel Medsystems, Inc. is a clinical-stage medical technology company focused on developing advanced solutions for women's healthcare, specifically in the area of endometrial ablation. Founded in 2009 and based in Emeryville, California, the company specializes in proprietary cryo-ablation delivery technologies. Its innovative approach combines cryothermic energy with a user-friendly, self-contained handheld device, eliminating the need for separate control units or additional capital equipment. This design aims to enhance the treatment experience for female patients while meeting the high standards expected by healthcare providers.
Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.
Xlumena, Inc. specializes in developing image-guided therapeutic endoscopy products designed to enhance minimally invasive medical procedures. The company offers a range of innovative solutions, including the AXIOS Stent and Delivery System for treating pancreatic pseudocysts, and the NAVIX Access Device, which also addresses this condition. Additionally, Xlumena has created a self-expanding anchor stent for bile duct stenting, an integrated system for reliable pseudocyst drainage, and a method for repairing hiatal hernias from within the gastrointestinal lumen. Founded in 2007 and based in Mountain View, California, Xlumena operates as a subsidiary of Boston Scientific Corporation since April 2015.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
Interlace Medical, Inc. specializes in the design and development of medical devices aimed at interventional gynecologists for office-based procedures. The company focuses on treating gynecological diseases and conditions that have traditionally required surgical intervention in an operating room setting. Among its notable products is the MyoSure hysteroscopic tissue removal system, which is specifically designed for the removal of submucosal fibroids and polyps. Through its innovative solutions, Interlace Medical seeks to enhance the efficiency and effectiveness of gynecological treatments.
Mako Surgical is a medical device company that specializes in advanced robotic arm solutions and orthopedic implants for minimally invasive knee and hip procedures. The company is known for its flagship product, MAKOplasty, which provides a restorative surgical option for orthopedic surgeons to address early to mid-stage osteoarthritic conditions in patients. The core technology includes a robotic arm interactive orthopedic system that features a tactile robotic arm and an integrated bone cutting instrument, along with a visualization component that assists surgeons with pre-operative and intra-operative guidance. This innovative approach facilitates tissue-sparing bone removal and ensures precise implant insertion and alignment. Founded in 2004 and headquartered in Florida, Mako Surgical has gained recognition for its rapid growth and commitment to customer service in the medical technology sector.
Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
Mako Surgical is a medical device company that specializes in advanced robotic arm solutions and orthopedic implants for minimally invasive knee and hip procedures. The company is known for its flagship product, MAKOplasty, which provides a restorative surgical option for orthopedic surgeons to address early to mid-stage osteoarthritic conditions in patients. The core technology includes a robotic arm interactive orthopedic system that features a tactile robotic arm and an integrated bone cutting instrument, along with a visualization component that assists surgeons with pre-operative and intra-operative guidance. This innovative approach facilitates tissue-sparing bone removal and ensures precise implant insertion and alignment. Founded in 2004 and headquartered in Florida, Mako Surgical has gained recognition for its rapid growth and commitment to customer service in the medical technology sector.
Altea Therapeutics Corporation develops and commercializes transdermal drug delivery systems. It offers PassPort patch, a skin patch that uses short bursts of focused thermal energy to create tiny channels in the surface of the skin and these channels permit the flow of proteins, peptides, carbohydrates, and small molecules into the body without the use of needles. The company also provides Transdermal vaccine patch, a delivery system for water-soluble drugs and proteins; disease prevention products; insulin skin patch, a non-injectable daily insulin product; and opioid patches that provide delivery of opioids and incorporates the layers of deterrents. Altea Therapeutics Corporation was formerly known as Altea Development Corporation. The company was founded in 1998 and is based in Atlanta, Georgia. As of May 9, 2012, Altea Therapeutics Corporation operates as a subsidiary of Nitto Denko Corp.
TherOx, Inc. is a medical device company based in Irvine, California, focused on enhancing the treatment standards for heart attack patients. Founded in 1994, the company specializes in developing and manufacturing dissolved oxygen delivery systems, specifically through its proprietary SuperSaturated Oxygen Therapy (SSO2). The TherOx DownStream system is a mobile device that works in conjunction with a cartridge and console to create a superoxygenated solution mixed with the patient’s blood, which is then delivered to the coronary arteries. This innovative approach aims to restore blood flow and promote healing in damaged heart tissue. In addition to its primary application in heart attack treatment, TherOx has identified potential uses for its technology in other medical fields, including stroke, oncology, and wound care. The company holds 20 issued patents, with additional applications pending. As of June 2019, TherOx operates as a subsidiary of ZOLL Medical Corporation.
Nina McLemore, LLC designs clothing for women. It offers jackets, fabrics, skirts, pants, hand crafted jewelries and accessories, suiting, casual wools, cottons, evening collections, essentials, and silks. The company provides its products through stores primarily in New York, San Francisco, Seattle, Aspen, Cleveland, Nantucket, Chestertown, and Easton. Nina McLemore, LLC was founded in 2002 and is based in New York, New York.
Redpoint Bio is following a strategy focused on preserving the value of the License and Commercialization Agreement it entered into with International Flavors and Fragrances, Inc. (IFF), a global leader in the food and beverage industry. As part of this strategy, the Company continues its efforts to reduce its liabilities and sell its remaining assets. Given its lack of resources, the Company is not currently performing any research and development activities.
Metra Biosystems
Venture Round in 1992
Metra Biosystems develops and commercializes diagnostic products for the detection and management of metabolic bone and joint diseases and disorders.